Amplification of HER2 is a Marker for Global Genomic Instability

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2008 Oct 16

PMID 18854030

Citations 15

Authors

Rachel E Ellsworth

Darrell L Ellsworth

Heather L Patney

Brenda Deyarmin

Brad Love

Jeffrey A Hooke

Craig D Shriver

Affiliations

Soon will be listed here.

Abstract

Background: Genomic alterations of the proto-oncogene c-erbB-2 (HER-2/neu) are associated with aggressive behavior and poor prognosis in patients with breast cancer. The variable clinical outcomes seen in patients with similar HER2 status, given similar treatments, suggests that the effects of amplification of HER2 can be influenced by other genetic changes. To assess the broader genomic implications of structural changes at the HER2 locus, we investigated relationships between genomic instability and HER2 status in patients with invasive breast cancer.

Methods: HER2 status was determined using the PathVysion assay. DNA was extracted after laser microdissection from the 181 paraffin-embedded HER2 amplified (n=39) or HER2 negative (n=142) tumor specimens with sufficient tumor available to perform molecular analysis. Allelic imbalance (AI) was assessed using a panel of microsatellite markers representing 26 chromosomal regions commonly altered in breast cancer. Student t-tests and partial correlations were used to investigate relationships between genomic instability and HER2 status.

Results: The frequency of AI was significantly higher (P<0.005) in HER2 amplified (27%) compared to HER2 negative tumors (19%). Samples with HER2 amplification showed significantly higher levels of AI (P<0.05) at chromosomes 11q23, 16q22-q24 and 18q21. Partial correlations including ER status and tumor grade supported associations between HER2 status and alterations at 11q13.1, 16q22-q24 and 18q21.

Conclusion: The poor prognosis associated with HER2 amplification may be attributed to global genomic instability as cells with high frequencies of chromosomal alterations have been associated with increased cellular proliferation and aggressive behavior. In addition, high levels of DNA damage may render tumor cells refractory to treatment. In addition, specific alterations at chromosomes 11q13, 16q22-q24, and 18q21, all of which have been associated with aggressive tumor behavior, may serve as genetic modifiers to HER2 amplification. These data not only improve our understanding of HER in breast pathogenesis but may allow more accurate risk profiles and better treatment options to be developed.

Citing Articles

CNVs in 8q24.3 do not influence gene co-expression in breast cancer subtypes.

Hernandez-Gomez C, Hernandez-Lemus E, Espinal-Enriquez J Front Genet. 2023; 14:1141011.

PMID: 37274786 PMC: 10236314. DOI: 10.3389/fgene.2023.1141011.

Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer.

Castellanos G, Valbuena D, Perez E, Villegas V, Rondon-Lagos M Breast Cancer (Dove Med Press). 2023; 15:189-211.

PMID: 36923397 PMC: 10010144. DOI: 10.2147/BCTT.S383759.

Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy.

Gu Y, Zhang Z, Ten Dijke P Cell Mol Immunol. 2023; 20(4):318-340.

PMID: 36823234 PMC: 10066239. DOI: 10.1038/s41423-023-00980-8.

Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells.

Polikarpov D, Liang L, Care A, Sunna A, Campbell D, Walsh B Biomolecules. 2019; 9(12).

PMID: 31816991 PMC: 6995529. DOI: 10.3390/biom9120820.

Identifying neoantigens for use in immunotherapy.

Hutchison S, Pritchard A Mamm Genome. 2018; 29(11-12):714-730.

PMID: 30167844 PMC: 6267674. DOI: 10.1007/s00335-018-9771-6.

References

Frank C, McClatchey K, Devaney K, Carey T . Evidence that loss of chromosome 18q is associated with tumor progression. Cancer Res. 1997; 57(5):824-7. View

Ellsworth R, Hooke J, Love B, Kane J, Patney H, Ellsworth D . Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumors. Breast Cancer Res Treat. 2007; 107(2):259-65. DOI: 10.1007/s10549-007-9547-2. View

Pollack J, Perou C, Alizadeh A, Eisen M, Pergamenschikov A, Williams C . Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999; 23(1):41-6. DOI: 10.1038/12640. View

Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L . Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17(9):2639-48. DOI: 10.1200/JCO.1999.17.9.2639. View

Isola J, Chu L, DeVries S, Matsumura K, Chew K, Ljung B . Genetic alterations in ERBB2-amplified breast carcinomas. Clin Cancer Res. 2000; 5(12):4140-5. View

Medintz I, Lee C, Wong W, Pirkola K, Sidransky D, Mathies R . Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis. Genome Res. 2000; 10(8):1211-8. PMC: 310921. DOI: 10.1101/gr.10.8.1211. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Treish I, Schwartz R, Lindley C . Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm. 2000; 57(22):2063-76; quiz 2077-9. View

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

10.

Welcsh P, King M . BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001; 10(7):705-13. DOI: 10.1093/hmg/10.7.705. View

11.

Kauraniemi P, Barlund M, Monni O, Kallioniemi A . New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res. 2001; 61(22):8235-40. View

12.

Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M . Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001; 93(24):1852-7. DOI: 10.1093/jnci/93.24.1852. View

13.

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View

14.

Dellas A, Torhorst J, Schultheiss E, Mihatsch M, Moch H . DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer. Clin Cancer Res. 2002; 8(5):1210-6. View

15.

Ellsworth D, Shriver C, Ellsworth R, Deyarmin B, Somiari R . Laser capture microdissection of paraffin-embedded tissues. Biotechniques. 2003; 34(1):42-4, 46. DOI: 10.2144/03341bm05. View

16.

Dressman M, Baras A, Malinowski R, Alvis L, Kwon I, Walz T . Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res. 2003; 63(9):2194-9. View

17.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

18.

Ellsworth R, Ellsworth D, Lubert S, Hooke J, Somiari R, Shriver C . High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomarkers Prev. 2003; 12(9):915-9. View

19.

Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy J, Rouas G . Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol. 2003; 24(1):201-9. View

20.

Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adelaide J . Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene. 2004; 23(14):2564-75. DOI: 10.1038/sj.onc.1207361. View